EUZ Eckert & Ziegler Strahlen- und Medizintechnik AG

EQS-News: Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden

EQS-News: Eckert & Ziegler SE / Key word(s): Expansion/Miscellaneous
Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden

20.08.2024 / 17:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Berlin, 20.08.2024. In the presence of the Saxon State Ministers Martin Dulig and Thomas Schmidt as well as the Mayor of Dresden Dirk Hilbert, the medical technology company Eckert & Ziegler today inaugurated its new 1,700 square meter facilities in Dresden with around 200 guests. The Dresden-Rossendorf site produces and delivers high-tech systems for the production of radiopharmaceuticals worldwide and provides services for the handling and disposal of radioactive products in cancer medicine. Eckert & Ziegler is investing up to € 50 million in the expansion of the production site. The new buildings that have now been completed are the basis for the company's further expansion and create the foundation for employement of up to 100 additional highly qualified staff in plant engineering and radiopharmacy in Saxony.

Dr. Gunnar Mann, member of the Group Executive Committee of Eckert & Ziegler SE: “The expansion of our production capacities is the answer to the rapidly growing demand for nuclear medicine compounds for cancer diagnostics and therapy. We currently have around 100 employees at our Rossendorf site, and we want to be able to double this number.”

Martin Dulig, Minister of State for Economic Affairs, Labor and Transport of the Free State of Saxony: “The new building is proof of the growing success of Eckert & Ziegler in the region, but also of the fertile conditions that this location offers. The company is now making a further contribution to ensuring that we in Saxony, especially in our state capital and in Radeberg - together with the scientific institutions and the nuclear medicine companies active here and their well over 1,000 employees - are a leading radiopharmaceutical center in Europe!”

Thomas Schmidt, Minister of State for Regional Development of the Free State of Saxony: “Dresden-Rossendorf is becoming a Silicon Valley of radiopharmacy. With the neighboring 'Helmholtz-Zentrum', a large number of available specialists, a growing number of companies and an ideal infrastructure for further investments, Saxony has a rapidly developing, highly innovative technology cluster in this field.”

Dirk Hilbert, Lord Mayor of the City of Dresden: “Our strategy is the right one. We are investing EUR 6.8 million in the expansion of the Dresden-Rossendorf commercial area in order to make such establishments possible. We are happy that an internationally leading company such as Eckert & Ziegler has chosen Dresden as the location for their expansion. In addition to the semiconductor industry, we are thus setting a further focus on cutting-edge medical and nuclear research.”

Photos of the event can be found here:

About Eckert & Ziegler
With over 1,000 employees, Eckert & Ziegler SE is one of the leading providers of isotope technology components for nuclear medicine and radiotherapy. At its locations worldwide, the company offers services and products in the field of radiopharmacy, from early development to commercialization. The Eckert & Ziegler shares (ISIN DE0005659700) are listed on the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Isotope Technologies Dresden GmbH (ITD)
, a wholly owned subsidiary of Eckert & Ziegler SE based in Dresden, specializes in plant engineering for handling radioactive materials and offers tailor-made hot cell solutions to international customers in the healthcare sector, industry and research and development facilities.

Gamma-Service Recycling GmbH (GSR), a wholly owned subsidiary of Eckert & Ziegler SE based in Leipzig, specializes in handling and transporting radioactive materials in Germany and abroad.

Your contact for further inquiries:

Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin,

Marius Wölfges, Marketing
Phone +49 (0) 30 / 94 10 84-461,   

Karolin Riehle, Investor Relations & PR
Phone: +49 (0) 30 / 94 10 84-138,



20.08.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: Eckert & Ziegler SE
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 38
Fax:
Internet:
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDax,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1970673

 
End of News EQS News Service

1970673  20.08.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1970673&application_name=news&site_id=research_pool~~~9efe1c65-8ece-4ff7-9608-f21c8e0a38a3
EN
20/08/2024

Underlying

Reports on Eckert & Ziegler Strahlen- und Medizintechnik AG

 PRESS RELEASE

EQS-News: Eckert & Ziegler: Record year 2024 with new all-time highs

EQS-News: Eckert & Ziegler SE / Key word(s): Annual Results/Forecast Eckert & Ziegler: Record year 2024 with new all-time highs 27.03.2025 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, 27 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) achieved a new record in the 2024 financial year with sales of € 295.8 million based on the preliminary annual financial statements*. Compared to the previous year, sales increased by almost € 50 million (+20%). EBIT before special items from continuing operations (adjusted EBIT)...

 PRESS RELEASE

EQS-News: Eckert & Ziegler: Rekordjahr 2024 mit neuen Höchstmarken

EQS-News: Eckert & Ziegler SE / Schlagwort(e): Jahresergebnis/Prognose Eckert & Ziegler: Rekordjahr 2024 mit neuen Höchstmarken 27.03.2025 / 07:45 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Berlin, den 27. März 2025. Die Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) erreichte auf Basis des vorläufigen Jahresabschlusses* im Geschäftsjahr 2024 mit einem Umsatz von 295,8 Mio. € eine neue Rekordmarke. Im Vergleich zum Vorjahr stieg der Umsatz um knapp 50 Mio. € (+20%). Das EBIT vor Sondereinflüssen aus fortgeführten Geschäftsbereic...

 PRESS RELEASE

EQS-News: Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-...

EQS-News: Eckert & Ziegler SE / Key word(s): Agreement/Incoming Orders Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities 25.03.2025 / 09:30 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, DE & New York, USA, 25 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and Actinium Pharmaceuticals, Inc. announced that they have entered into an agreement for the supply of Actinium-225 (Ac-225). With this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler’s ...

 PRESS RELEASE

EQS-News: Eckert & Ziegler beliefert Actinium Pharmaceuticals mit Ac-2...

EQS-News: Eckert & Ziegler SE / Schlagwort(e): Vereinbarung/Auftragseingänge Eckert & Ziegler beliefert Actinium Pharmaceuticals mit Ac-225 für umfangreiches Entwicklungsprogramm 25.03.2025 / 09:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Berlin, DE & New York, USA, 25. März 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) und Actinium Pharmaceuticals, Inc. gaben bekannt, dass sie eine Vereinbarung über die Lieferung von Actinium-225 (Ac-225) geschlossen haben. Mit dieser Vereinbarung erhält Actinium Pharmaceuticals Zugang...

 PRESS RELEASE

EQS-News: Eckert & Ziegler and AtomVie Global Radiopharma Sign a Globa...

EQS-News: Eckert & Ziegler SE / Key word(s): Incoming Orders/Agreement Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply 20.03.2025 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, DE & Hamilton, ON, CA, 20 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and AtomVie Global Radiopharma Inc. (AtomVie) today announced a global supply agreement. Eckert & Ziegler will provide its high-quality non-carrier added Lutetium-177 chloride (n.c.a. Lu-177, Theralugand®) to support A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch